The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
Open accessAbstract
Objectives: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored. Materials and Methods: A cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806). Key inclusion criteria included recurrent or metastatic disease, failure of prior systemic therapy, and PD-L1 expression on ≥1% of tumor or stroma cells (per a prototype immunohistochemistry assay). Patients received pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until confirmed disease progression or unacceptable toxicity. Primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by investigator review. Results: Twenty-six patients with PD-L1-positive SGC were enrolled and treated; median age was 57 years, 88% were men, and 74% had received prior therapy for recurrent/metastatic disease. Confirmed objective response rate after median follow-up of 20 months was 12% (95% confidence interval, 2%-30%), with 3 patients achieving partial response; there were no complete responses. Median duration of response was 4 months (range, 4 to 21 mo). Treatment-related adverse events occurred in 22 patients (85%), resulting in discontinuation in 2 patients and death in 1 (interstitial lung disease); those occurring in ≥15% of patients were diarrhea, decreased appetite, pruritus, and fatigue. Conclusions: Pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1-positive SGC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“ORR (95% CI) (%)* 3 12 (2-30) CR 0 0 (0-13) PR 3† 12 (2-30) SD 12 46 (27-67) SD≥ 6 mo 3 12 (2-30) PD 11 42 (23-63) Disease control rate (95% CI) (%)‡ 15 58 (37-77) Clinical benefit rate (95% CI) (%)§ 6 23 (9-44) Time to response, median (range) (mo) 3 1.”
Self-citation
Cited by
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Management of Salivary Gland Malignancy: ASCO Guideline
Geiger, J. L., Ismaila, N., Beadle, B., Caudell, J. J., Chau, N., Deschler, D., Glastonbury, C., Kaufman, M., Lamarre, E., Lau, H. Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00449 · Cited by 441
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
Ran, X., & Yang, K. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s140687 · Cited by 51
Metadata
- Authors
- Cohen, R. B., Delord, J.-P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R.-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J., & Keam, B.
- Venue
- American Journal of Clinical Oncology
- Published
- 2018-11
- Volume
- 41
- Issue
- 11
- Pages
- 1083-1088
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W2792603138
- Cited by
- 211
- References
- 2
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. https://app.cochat.ai/papers/10.1097/coc.0000000000000429
- The paper
- Cohen, R. B., Delord, J.-P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R.-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J., & Keam, B. (2018). Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0000000000000429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.